LIT™ in Breast Cancer

Detecting cancer's spread, for a brighter future ahead.

Our transformative technology has been patented in cancer

Patent "MONITORING CANCER RECURRENCE AND PROGRESSION" granted in Europe, USA, and Japan.

The most commonly diagnosed cancer worldwide

In 2020, there were approximately 2.3 million new cases and 685,000 related deaths globally*.

In the UK, there were 48,387 new cases of breast cancer in 2019, resulting in 9,525 recorded deaths, mostly due to metastatic breast cancer. Currently, 57,215 patients are living with metastatic breast cancer**.

*Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec

**Palmieri C, Owide J, Fryer K. Estimated Prevalence of Metastatic Breast Cancer in England, 2016-2021. JAMA Netw Open. 2022 Dec

Early detection of metastatic disease using a simple, affordable, and readily available test would be a gamechanger for breast cancer patients.

LIT™ could monitor patients' response to treatment and detect recurrent disease at an early stage, improving patient outcomes and experiences. This cost-effective test could replace expensive MRI/PET scans and result in long-term cost savings for the NHS, with the potential to improve patient outcomes, lengthen lives, and reduce the number of deaths from breast cancer.